BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 24, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Catena idebenone: Phase III data

Top-line data from the double-blind, European Phase III MICONOS trial in 232 patients showed that all doses of oral Catena missed the primary endpoint of significantly improving ICARS score from baseline to week 52 vs. placebo. Catena also missed the secondary endpoints of a significantly greater proportion of patients achieving a 2.5 point improvement in ICARS score and change from baseline in FARS score vs. placebo. There was also no significant difference...

Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >